Fig. 2

Visits for enrollment, treatment and assessments. After screening for eligibility and allocation (visits − 3 to − 1), 18 study visits (visits 0–17) are planned for treatment and assessments during the treatment period, followed by 8 additional visits (visits 18–25) during the 2-year follow-up. ¹Resection is performed in week 0 (visit − 2); ²weeks 5–10: 6 cycles of concomitant radiochemotherapy; ³weeks 15, 19, 23, 27, 31, 35): 6 cycles (days 1–5 of 28-day cycle) of adjuvant temozolomide (TMZ) chemotherapy; ⁴weeks 11–14: 4 priming vaccinations; ⁵weeks 17, 21, 25: 3 boost vaccinations; ⁶weeks 16, 28, 37: magnetic resonance imaging (MRI) scans; ⁷weeks 5, 10: clinical, clinical chemistry, hematological, hemostaseological examinations and adverse events (AE), concomitant medication and KPS assessments; ⁸weeks 11–14: clinical, clinical chemistry, hematological, hemostaseological examinations and AE and concomitant medication assessments; ⁹weeks 15, 17, 21, 25, 29, 33, 38: clinical, clinical chemistry, hematological, hemostaseological examinations and AE and concomitant medication assessments; ¹⁰week 10: neurological performance and quality of life assessments; ¹¹weeks 15, 29, 38: KPS, neurological performance and quality of life assessments; ¹²tumor tissue and blood for translational research studies are sampled during resection, leukapheresis and at the 7 time points of vaccination; ¹³pregnancy tests are performed at monthly intervals until 6 months after the treatment period; *vaccination arm only